Lupus & antiphospholipid syndrome
Impact of SARS-CoV-2 pre-delta/delta and omicron variants on clinical outcomes in a systemic lupus erythematosus cohort from Puerto Rico
Authors' conclusion
In summary, is this group of Puerto Ricans with SLE, a high proportion had COVID-19, but disease exacerbation, hospitalization, and mortality rates were low.
Study context
- Population
- Adult Puerto Ricans with systemic lupus erythematosus (SLE); SARS-CoV-2 infection confirmed by PCR or antigen tests169 with COVID-19
- Participants
- 347 participants
- Exposure
- COVID-19 during the Pre-delta/Delta period vs during the Omicron period
- Pre-delta/Deltan = 22
- Omicronn = 147reference
- Outcome
- Clinical outcomes of COVID-19 (SLE exacerbations, hospitalizations, mortality) in SLE patients
Main finding
As reported in the abstract
- COVID-19 in the SLE cohort
- 169 (48.7%)
- COVID-19 proportion significantly higher than in adult general population of Puerto Rico
- 25.7%
- Lupus flares
- 3.0%
- Hospitalizations
- 3.6%
- Mortality
- 0.6%
Observational data: associations, not effects.
Further findings
Clinical differences between periods
- Pre-delta/Delta more likely to have oral ulcers, anti-Smith antibodies and CKD
- Omicron more likely to have COVID-19 symptoms (rhinorrhea, sore throat, cough)
Original publication
Impact of SARS-CoV-2 pre-delta/delta and omicron variants on clinical outcomes in a systemic lupus erythematosus cohort from Puerto Rico. Lupus. Published 27 February 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →